Last updated: October 1, 2026
Retrovir, the brand name for zidovudine or AZT, is a mature antiretroviral with limited current commercial value. FDA approval in 1987 made it the first approved treatment for HIV infection, but patent expiry, generic substitution, treatment toxicity, resistance, and replacement by newer combination regimens have reduced its role. Retrovir remains clinically relevant in selected HIV and perinatal settings, but its financial trajectory is structurally declining.
Standalone Retrovir revenue is not publicly disclosed by ViiV Healthcare, GSK, or their parent-company reporting. The product is no longer identified as a material revenue driver in current HIV pharmaceutical reporting. Its market is now primarily a low-price generic market, with residual branded demand in specific formulations and institutional channels.
What is Retrovir and how is zidovudine used today?
Retrovir contains zidovudine, a nucleoside reverse transcriptase inhibitor, or NRTI. It inhibits HIV reverse transcriptase after intracellular conversion to its active triphosphate form.
The FDA approved Retrovir in 1987 for HIV infection. Its clinical uses have narrowed as combination antiretroviral therapy improved. Current use generally falls into four categories:
| Use area |
Current commercial relevance |
| Adult HIV treatment |
Low |
| Pediatric HIV treatment |
Selective |
| Prevention of maternal-fetal HIV transmission |
Targeted, but substantially reduced from historical use |
| Neonatal prophylaxis |
Persistent institutional demand in defined risk settings |
| Single-agent HIV therapy |
Obsolete under modern treatment standards |
Retrovir is generally used in combination with other antiretrovirals when prescribed for HIV treatment. It is not recommended as monotherapy because of resistance risk and inferior durability compared with modern combination regimens (U.S. Department of Health and Human Services, 2024).
The principal safety limitations are anemia, neutropenia, myopathy, mitochondrial toxicity, and lactic acidosis. These concerns are more consequential with long-term exposure and have supported substitution by better-tolerated NRTIs.
When did Retrovir lose market exclusivity?
Retrovir lost practical market exclusivity in the United States after the expiration of its core patent protection and the launch of generic zidovudine products.
| Milestone |
Date or period |
Commercial effect |
| Zidovudine identified as an antiviral compound |
1960s |
Created the scientific basis for later HIV development |
| FDA approval of Retrovir |
March 19, 1987 |
Established the first approved HIV treatment |
| Core U.S. patent issued |
1988 |
Protected the active pharmaceutical ingredient and related use |
| Core patent expiration |
Approximately 2005 |
Opened the U.S. market to generic competition |
| Generic zidovudine availability |
Mid-2000s onward |
Compressed price and branded demand |
| Modern combination therapy dominance |
2010s onward |
Reduced use of zidovudine-based regimens |
| Current market position |
2020s |
Legacy, niche, and institutional product |
The U.S. patent commonly associated with zidovudine is U.S. Patent No. 4,724,232, assigned to the relevant Burroughs Wellcome interests. The patent issued in 1988 and reached the end of its ordinary term in the mid-2000s. Patent-term adjustments, pediatric extensions, and jurisdiction-specific rights could affect the precise expiration analysis, but they did not preserve a meaningful branded monopoly into the current decade.
What patents protect Retrovir and zidovudine?
The original patent estate covered zidovudine and its use against retroviral infections. That protection was commercially decisive in the late 1980s and 1990s but is no longer an effective barrier to generic entry.
Active-ingredient patents
The core active-ingredient patent covered 3'-azido-3'-deoxythymidine, the chemical name for zidovudine. Once that protection expired, generic manufacturers could market the same active ingredient subject to FDA approval requirements.
Formulation patents
Retrovir has been marketed in multiple dosage forms, including:
- 100 mg capsules;
- oral solution;
- injectable formulation;
- pediatric liquid products.
These dosage forms do not create a durable modern exclusivity position. Standard immediate-release zidovudine formulations are technically established, and generic manufacturers can usually develop them without significant formulation innovation.
Method-of-use patents
Historical method-of-use rights related to treatment of HIV infection and prevention of maternal-fetal transmission. Those rights have expired or lost practical commercial force. Current zidovudine use is governed primarily by clinical guidelines, labeling, and hospital protocols rather than enforceable exclusivity.
Manufacturing and process protection
Zidovudine synthesis is commercially established. Manufacturing know-how, regulatory compliance, impurity control, and supply reliability can affect competitive performance, but they do not create a meaningful barrier comparable to a protected biologic process or complex drug-delivery system.
What is the Orange Book status of Retrovir?
Retrovir is an FDA-approved small-molecule product, not a biologic. Its regulatory position is therefore based on the Abbreviated New Drug Application pathway for generic equivalents rather than the biosimilar pathway.
The commercial relevance of Orange Book-listed patents is minimal because the principal patent barriers have expired. Generic manufacturers can seek approval for zidovudine capsules and oral solutions through ANDAs, subject to bioequivalence, chemistry, manufacturing, and labeling requirements.
No biosimilar pathway applies to Retrovir. Zidovudine is a chemically synthesized small molecule, so competition is described as generic competition, not biosimilar competition.
Which companies compete with Retrovir?
Competition has shifted from branded product rivalry to generic supply and substitution.
Originator and rights holders
Retrovir was developed by Burroughs Wellcome, which later became part of Glaxo Wellcome and then GSK. ViiV Healthcare, the HIV-focused company owned by GSK, Pfizer, and Shionogi, is the principal commercial entity associated with GSK’s HIV portfolio. Retrovir does not occupy a strategic position comparable to ViiV products such as Tivicay, Triumeq, Dovato, or Rukobia.
Generic manufacturers
Generic zidovudine has been marketed by multiple manufacturers over time, including major U.S. and international generic companies. Availability can vary by dosage form, country, and procurement contract. The leading competitive factors are:
- lowest acquisition cost;
- supply continuity;
- FDA or local regulatory approval;
- pediatric and oral-solution availability;
- government and hospital tender access.
In many markets, the relevant competitors are other antiretroviral ingredients rather than other zidovudine manufacturers. Tenofovir disoproxil fumarate, tenofovir alafenamide, emtricitabine, lamivudine, abacavir, and dolutegravir have displaced zidovudine in routine treatment.
How does Retrovir compare with modern HIV drugs?
Retrovir has a materially weaker commercial and clinical position than newer integrase inhibitor-based products.
| Product or class |
Primary advantage over zidovudine |
Commercial position |
| Dolutegravir-based regimens |
High potency, high barrier to resistance, simpler dosing |
Strong |
| Bictegravir-based regimens |
Single-tablet treatment with favorable tolerability |
Strong |
| Tenofovir-based regimens |
Broad use in HIV treatment and prevention |
Strong |
| Abacavir-based regimens |
Established alternative in selected patients |
Moderate |
| Zidovudine |
Long clinical history and neonatal utility |
Legacy and targeted |
Modern HIV therapy prioritizes efficacy, tolerability, adherence, resistance protection, and reduced pill burden. Retrovir performs poorly against those criteria for routine adult treatment. Its continued use depends on specific clinical circumstances, including pregnancy-related protocols, neonatal prophylaxis, drug-interaction considerations, and treatment histories involving resistance or intolerance.
What is the financial trajectory for Retrovir?
Retrovir’s financial trajectory is declining and structurally irreversible as a branded product.
Historical revenue profile
Retrovir generated significant early revenue because it was the first approved HIV treatment and initially had no therapeutic substitute. Its value increased through pediatric formulations, combination use, and demand created by the expanding HIV epidemic.
That position eroded as:
- combination therapy replaced single-agent treatment;
- generic manufacturers entered after patent expiry;
- safety and tolerability concerns became more important;
- newer NRTIs and integrase inhibitors improved outcomes;
- public-health programs adopted lower-cost and more effective regimens.
Current revenue profile
Neither GSK nor ViiV publicly reports standalone Retrovir revenue in current financial disclosures. The product is grouped within broader HIV or established-product categories, if reported at all. This prevents a reliable current annual-sales estimate from public company filings.
The available commercial evidence supports a low-revenue assessment:
| Financial factor |
Effect on Retrovir |
| Patent expiry |
Eliminated premium pricing |
| Generic substitution |
Reduced branded volume |
| Limited modern guideline use |
Reduced prescription demand |
| Institutional and pediatric demand |
Preserved residual sales |
| Established manufacturing |
Reduced production cost |
| Low differentiation |
Limited pricing power |
| ViiV portfolio focus on newer products |
Reduced strategic investment |
Retrovir may continue to produce positive contribution margin where manufacturing and distribution costs are low. That does not make it a growth asset. The product’s value is more likely to reflect portfolio continuity, regulatory maintenance, and supply commitments than incremental revenue expansion.
What formulation patents protect Retrovir’s commercial opportunity?
No formulation strategy is likely to restore substantial exclusivity.
The oral solution and capsule products use conventional immediate-release technology. They do not have the technical complexity associated with liposomal formulations, long-acting injectables, extended-release systems, or device-based delivery. A new zidovudine formulation could theoretically obtain patent protection, but its commercial prospects would be constrained by the availability of better-tolerated antiretrovirals.
The pediatric liquid formulation has greater practical importance than its patent value. Hospitals, public-health programs, and pediatric specialists may require a liquid product even when adult demand is minimal. This supports a small but persistent market.
Are there Paragraph IV challenges involving Retrovir?
Paragraph IV litigation was relevant during the generic-entry period, when ANDA applicants could challenge listed patents as invalid, unenforceable, or not infringed. The principal commercial issue has passed because the core exclusivity period expired years ago.
Current generic competition is therefore unlikely to depend on a new Paragraph IV event involving the original Retrovir patent estate. Any litigation today would more likely concern:
- supply or quality disputes;
- labeling;
- manufacturing compliance;
- newer formulation claims;
- contractual or distribution matters.
The absence of a current patent barrier means a new entrant generally faces regulatory and commercial execution risk rather than originator patent litigation risk.
What patent litigation and settlement agreements affect Retrovir?
Retrovir’s material patent disputes were concentrated in the historical period surrounding the first HIV treatment market and generic entry. No current, high-value patent litigation is broadly associated with Retrovir comparable to disputes involving long-acting HIV products, combination tablets, or biologic therapies.
Settlement agreements from the historical generic-entry period may have influenced launch timing in specific jurisdictions, but they do not define the current market. The economic center of gravity has moved from patent litigation to procurement, supply, and clinical substitution.
What generic launch scenarios exist for zidovudine?
The most likely market scenarios are:
| Scenario |
Probability |
Market consequence |
| Continued low-volume generic supply |
High |
Stable residual demand with price pressure |
| Further branded withdrawal |
High |
Generic substitution increases |
| Regional supply shortages |
Moderate |
Temporary price and procurement volatility |
| New branded formulation |
Low |
Limited commercial upside |
| Material return to adult first-line use |
Very low |
No clinical basis under current standards |
The main commercial risk is not rapid generic entry. It is gradual market abandonment if manufacturers discontinue low-volume presentations, particularly pediatric oral solution or injectable products. That risk can create localized supply problems without improving the originator’s long-term financial outlook.
How strong is the Retrovir patent estate?
The current patent estate is weak from a commercial perspective.
| Patent-estate factor |
Assessment |
| Core compound protection |
Expired |
| Method-of-use protection |
Expired or commercially ineffective |
| Formulation protection |
Limited |
| Manufacturing barriers |
Low to moderate |
| Regulatory exclusivity |
Expired |
| Generic entry risk |
High |
| Litigation leverage |
Low |
| Revenue defense |
Minimal |
Retrovir’s remaining defensibility comes from product familiarity, regulatory history, distribution relationships, and selective clinical demand. Those attributes can support continued sales but cannot recreate historical exclusivity.
What is the outlook for Retrovir through 2030?
Through 2030, zidovudine is likely to remain available as a low-cost legacy antiretroviral in selected markets. Volume should continue to decline in routine adult treatment, while neonatal, pediatric, pregnancy-related, and institutional use may provide a stable floor.
The product’s financial profile is best characterized as:
- declining branded revenue;
- low pricing power;
- high generic substitution;
- limited R&D investment;
- low probability of major patent-driven value creation;
- persistent but narrow clinical utility.
ViiV’s HIV growth strategy is centered on newer products and long-acting treatment, not on extending Retrovir’s lifecycle. Any remaining originator value is likely to come from efficient supply, portfolio completeness, and selective demand rather than market expansion.
Key Takeaways
- Retrovir is zidovudine, the first FDA-approved HIV treatment, approved in 1987.
- Core patent protection expired in the mid-2000s, allowing broad generic competition.
- Retrovir has no meaningful current biosimilar issue because zidovudine is a small-molecule drug.
- Orange Book and Paragraph IV issues are primarily historical rather than current commercial constraints.
- Routine adult use has been displaced by better-tolerated, more potent combination regimens.
- Residual demand remains in neonatal prophylaxis, pediatric treatment, selected pregnancy-related protocols, and institutional procurement.
- Standalone Retrovir revenue is not publicly disclosed by GSK or ViiV.
- The financial trajectory is declining, with limited probability of branded revenue recovery.
- The main current risks are generic price erosion and supply discontinuation, not patent litigation.
- Retrovir’s patent estate is commercially weak, but the product may remain clinically available through 2030 as a niche generic and legacy branded therapy.
Frequently Asked Questions
Is Retrovir still sold in the United States?
Yes. Zidovudine remains available through approved products and generic equivalents, although availability varies by formulation and manufacturer.
Is zidovudine the same as AZT?
Yes. AZT is the common abbreviation for zidovudine, the active ingredient in Retrovir.
Can generic zidovudine be substituted for Retrovir?
FDA-approved generic zidovudine products may be substituted under applicable state pharmacy laws and prescription requirements, subject to dosage form and product availability.
Why is zidovudine still used for newborns?
Zidovudine remains useful in selected neonatal prophylaxis protocols because of its historical evidence base, established dosing, and availability in pediatric formulations.
Does Retrovir have exclusivity for HIV prevention?
No meaningful current market exclusivity protects Retrovir for HIV prevention or treatment. Any ongoing use is based on clinical guidance and product availability rather than active patent protection.
References
-
Food and Drug Administration. (1987). Retrovir approval history and prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
GlaxoSmithKline plc. (2024). Annual report 2023. London, United Kingdom.
-
National Library of Medicine. (2024). Zidovudine: Drug information and labeling. DailyMed.
-
U.S. Department of Health and Human Services. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. ClinicalInfo.HIV.gov.
-
U.S. Department of Health and Human Services. (2024). Antiretroviral management of infants and children with perinatal HIV exposure or HIV infection. ClinicalInfo.HIV.gov.
-
U.S. Patent No. 4,724,232. (1988). Nucleosides with antiviral activity. United States Patent and Trademark Office.
